LONDON (Alliance News) - Cancer immunotherapies developer Scancell Holdings PLC on Friday said it has signed a strategic research collaboration agreement with researchers at the Karolinska Institutet in Sweden.
The company will work with researchers at the institute on exploring the scientific and clinical role of citrullinated proteins in the treatment of cancer.
"Our research has previously shown that citrullinated proteins are involved in the control of tumour growth, which led us to the development of the Moditope® platform," said Lindy Durrant, Scancell co-chief executive.
"We believe that this strategic collaboration with Karolinska will enhance our joint understanding of the role that citrullination plays in both cancer and rheumatoid arthritis, and will help us develop the Moditope platform to its full potential," she added.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)